| Jordan/Zalaznick Advisers Inc. | 95.9 | 4 | 4 |
| G2 | 51.7 | 3 | 0 |
| PitchBook Company Data | 41.3 | 1 | 1 |
| Forrester | 41.0 | 2 | 0 |
| Salesforce | 41.0 | 2 | 0 |
| Dunnhumby | 41.0 | 2 | 0 |
| HubSpot | 41.0 | 2 | 0 |
| Wrike Inc. | 41.0 | 2 | 0 |
| SuiteCRM | 41.0 | 2 | 0 |
| CB Insights | 41.0 | 2 | 0 |
| Salesforce | 41.0 | 2 | 0 |
| LiveRamp | 41.0 | 2 | 0 |
| Anove International | 41.0 | 2 | 0 |
| Web of Science | 40.0 | 0 | 5 |
| DBpedia | 25.8 | 1 | 0 |
| SourceForge | 25.8 | 1 | 0 |
| Gartner | 25.8 | 1 | 0 |
| Q389431 | 25.8 | 1 | 0 |
| FTSE 100 Index | 25.8 | 1 | 0 |
| Initng | 25.8 | 1 | 0 |
| Planisware | 25.8 | 1 | 0 |
| Bain & Company | 25.8 | 1 | 0 |
| DnB NORD | 25.8 | 1 | 0 |
| Object Windows Library | 25.8 | 1 | 0 |
| GIMPshop | 25.8 | 1 | 0 |
| CBRE Group | 25.8 | 1 | 0 |
| Dun & Bradstreet | 25.8 | 1 | 0 |
| The Hoover Company | 25.8 | 1 | 0 |
| JGnash | 25.8 | 1 | 0 |
| Mitsubishi Chemical Holdings | 25.8 | 1 | 0 |
| Open Source Media Framework | 25.8 | 1 | 0 |
| SimGear | 25.8 | 1 | 0 |
| BlazeDS | 25.8 | 1 | 0 |
| Q4041735 | 25.8 | 1 | 0 |
| Smb4K | 25.8 | 1 | 0 |
| Brian Halligan | 25.8 | 1 | 0 |
| Demandware | 25.8 | 1 | 0 |
| Salesforce Marketing Cloud | 25.8 | 1 | 0 |
| FAAC | 25.8 | 1 | 0 |
| London Stock Exchange Group | 25.8 | 1 | 0 |
| Q5793496 | 25.8 | 1 | 0 |
| Lattice engines | 25.8 | 1 | 0 |
| Leadspace | 25.8 | 1 | 0 |
| Libx | 25.8 | 1 | 0 |
| NDPMon | 25.8 | 1 | 0 |
| Open Computer Forensics Architecture | 25.8 | 1 | 0 |
| Salesloft | 25.8 | 1 | 0 |
| SixDegrees.com | 25.8 | 1 | 0 |
| TechTarget | 25.8 | 1 | 0 |
| Yext | 25.8 | 1 | 0 |
| ZoomInfo | 25.8 | 1 | 0 |
| Crunchbase | 25.8 | 1 | 0 |
| Minsky | 25.8 | 1 | 0 |
| Demandbase | 25.8 | 1 | 0 |
| PitchBook Data | 25.8 | 1 | 0 |
| Hoover's Inc. | 25.8 | 1 | 0 |
| InsideView | 25.8 | 1 | 0 |
| Slack | 25.8 | 1 | 0 |
| Similarweb | 25.8 | 1 | 0 |
| LeadGenius | 25.8 | 1 | 0 |
| Proxychains-ng | 25.8 | 1 | 0 |
| Snowflake Inc. | 25.8 | 1 | 0 |
| Engagio | 25.8 | 1 | 0 |
| FullContact | 25.8 | 1 | 0 |
| libmwaw | 25.8 | 1 | 0 |
| libodfgen | 25.8 | 1 | 0 |
| net-tools | 25.8 | 1 | 0 |
| Wrike (software) | 25.8 | 1 | 0 |
| Blue Obelisk Award | 25.8 | 1 | 0 |
| UpLead | 25.8 | 1 | 0 |
| Alexandr Nikitin | 25.8 | 1 | 0 |
| Shimon Haber | 25.8 | 1 | 0 |
| viking | 25.8 | 1 | 0 |
| 3DGE | 25.8 | 1 | 0 |
| DelphiDoom | 25.8 | 1 | 0 |
| Secure Access Service Edge | 25.8 | 1 | 0 |
| Q86068569 | 25.8 | 1 | 0 |
| Turquoise Europe | 25.8 | 1 | 0 |
| Data Communications | 25.8 | 1 | 0 |
| Reply.io | 25.8 | 1 | 0 |
| DataRobot, Inc. | 25.8 | 1 | 0 |
| Salesforce Lightning | 25.8 | 1 | 0 |
| Partners Group | 24.5 | 0 | 2 |
| company data | 24.5 | 0 | 2 |
| Category:Private equity portfolio companies | 24.5 | 0 | 2 |
| Illumio | 24.5 | 0 | 2 |
| 2014-205 - SEC Charges New York-Based Private Equity Fund Adviser With Misallocation Of Portfolio Company Expenses (NAID 144010395) | 24.5 | 0 | 2 |
| Exporting by Private Equity-Backed Portfolio Companies | 24.5 | 0 | 2 |
| The Missing Element of Private Equity: Creating Long-term Value Through Portfolio Company Board Diversity | 24.5 | 0 | 2 |
| Jim Hinton | 24.5 | 0 | 2 |
| Private equity portfolio company fees | 24.5 | 0 | 2 |
| Agencia Sheridan | 24.5 | 0 | 2 |
| Derrick App | 24.5 | 0 | 2 |
| TAMI | 24.5 | 0 | 2 |
| Human Dynamics | 24.5 | 0 | 2 |
| Bizpromo Databases | 24.5 | 0 | 2 |
| Penta Investments Limited | 15.5 | 0 | 1 |
| AXA | 15.5 | 0 | 1 |
| venture capital | 15.5 | 0 | 1 |
| 3i | 15.5 | 0 | 1 |
| Cerberus Capital Management | 15.5 | 0 | 1 |
| AS1 (networking) | 15.5 | 0 | 1 |
| AS3 (networking) | 15.5 | 0 | 1 |
| Advent International | 15.5 | 0 | 1 |
| Elizabeth Warren | 15.5 | 0 | 1 |
| private equity | 15.5 | 0 | 1 |
| Lone Star Funds | 15.5 | 0 | 1 |
| Tom Hicks | 15.5 | 0 | 1 |
| 3G Capital | 15.5 | 0 | 1 |
| Apollo Global Management | 15.5 | 0 | 1 |
| Permira | 15.5 | 0 | 1 |
| Platinum Equity | 15.5 | 0 | 1 |
| Bain Capital | 15.5 | 0 | 1 |
| Steven Rattner | 15.5 | 0 | 1 |
| Latvijas Televīzija | 15.5 | 0 | 1 |
| CVC Capital Partners | 15.5 | 0 | 1 |
| Cinven | 15.5 | 0 | 1 |
| DigitalBridge | 15.5 | 0 | 1 |
| IK Partners | 15.5 | 0 | 1 |
| Doughty Hanson & Co | 15.5 | 0 | 1 |
| EQT Partners | 15.5 | 0 | 1 |
| Esas Holding | 15.5 | 0 | 1 |
| Warburg Pincus | 15.5 | 0 | 1 |
| Segregated portfolio company | 15.5 | 0 | 1 |
| Kohlberg Kravis Roberts | 15.5 | 0 | 1 |
| lead generation | 15.5 | 0 | 1 |
| Q1613805 | 15.5 | 0 | 1 |
| industrial marketing | 15.5 | 0 | 1 |
| J.C. Flowers & Co. | 15.5 | 0 | 1 |
| Silver Lake | 15.5 | 0 | 1 |
| investment company | 15.5 | 0 | 1 |
| Simon & Schuster | 15.5 | 0 | 1 |
| Latvijas Radio | 15.5 | 0 | 1 |
| One Equity Partners | 15.5 | 0 | 1 |
| Open Application Group Integration Specification | 15.5 | 0 | 1 |
| Providence Equity Partners | 15.5 | 0 | 1 |
| Terra Firma Capital Partners | 15.5 | 0 | 1 |
| Lion Capital LLP | 15.5 | 0 | 1 |
| Bridgepoint Capital | 15.5 | 0 | 1 |
| growth capital | 15.5 | 0 | 1 |
| Charterhouse Capital Partners | 15.5 | 0 | 1 |
| contact information | 15.5 | 0 | 1 |
| Francisco Partners | 15.5 | 0 | 1 |
| Data enrichment | 15.5 | 0 | 1 |
| AlpInvest Partners | 15.5 | 0 | 1 |
| Network Abuse Clearinghouse | 15.5 | 0 | 1 |
| Omnes Capital | 15.5 | 0 | 1 |
| Pick operating system | 15.5 | 0 | 1 |
| Altor Equity Partners | 15.5 | 0 | 1 |
| Roger Altman | 15.5 | 0 | 1 |
| Private equity firm in France | 15.5 | 0 | 1 |
| speed networking | 15.5 | 0 | 1 |
| Starwood Capital Group | 15.5 | 0 | 1 |
| marketing intelligence | 15.5 | 0 | 1 |
| Vestar Capital Partners | 15.5 | 0 | 1 |
| DeA Capital | 15.5 | 0 | 1 |
| Nemir Kirdar | 15.5 | 0 | 1 |
| Latvian Puppet theater | 15.5 | 0 | 1 |
| Nordic Capital | 15.5 | 0 | 1 |
| AXA Private Equity | 15.5 | 0 | 1 |
| The Abraaj Group | 15.5 | 0 | 1 |
| account-based marketing | 15.5 | 0 | 1 |
| Actis Capital | 15.5 | 0 | 1 |
| Affinity Equity Partners | 15.5 | 0 | 1 |
| Allied Capital | 15.5 | 0 | 1 |
| Aloe private equity | 15.5 | 0 | 1 |
| Alta Communications | 15.5 | 0 | 1 |
| American Capital | 15.5 | 0 | 1 |
| American Securities | 15.5 | 0 | 1 |
| Arbejdsmarkedets Tillægspension | 15.5 | 0 | 1 |
| Arlington Capital Partners | 15.5 | 0 | 1 |
| Austin Ventures | 15.5 | 0 | 1 |
| Auto-lead Data Format | 15.5 | 0 | 1 |
| Avista Healthcare Partners | 15.5 | 0 | 1 |
| Baring Vostok Capital Partners | 15.5 | 0 | 1 |
| Blue Ridge Capital | 15.5 | 0 | 1 |
| Blum Capital | 15.5 | 0 | 1 |
| Brentwood Associates | 15.5 | 0 | 1 |
| Bruckmann, Rosser, Sherrill & Co. | 15.5 | 0 | 1 |
| Brynwood Partners | 15.5 | 0 | 1 |
| Business Development Company | 15.5 | 0 | 1 |
| CCMP Capital | 15.5 | 0 | 1 |
| CIVC Partners | 15.5 | 0 | 1 |
| CI Capital Partners | 15.5 | 0 | 1 |
| Calera Capital | 15.5 | 0 | 1 |
| Campbell Lutyens | 15.5 | 0 | 1 |
| Castle Harlan | 15.5 | 0 | 1 |
| L Catterton | 15.5 | 0 | 1 |
| Charlesbank Capital Partners | 15.5 | 0 | 1 |
| Charterhouse Group | 15.5 | 0 | 1 |
| Chicago Growth Partners | 15.5 | 0 | 1 |
| China-Africa Development Fund | 15.5 | 0 | 1 |
| China Venture Capital Association | 15.5 | 0 | 1 |
| Clarity Partners | 15.5 | 0 | 1 |
| Club deal | 15.5 | 0 | 1 |
| Cogent Partners | 15.5 | 0 | 1 |
| Motion Equity Partners | 15.5 | 0 | 1 |
| Coller Capital | 15.5 | 0 | 1 |
| Cordiant Capital Inc. | 15.5 | 0 | 1 |
| Cortec Group | 15.5 | 0 | 1 |
| Court Square Capital Partners | 15.5 | 0 | 1 |
| Criterion Capital Partners | 15.5 | 0 | 1 |
| CrossHarbor Capital Partners | 15.5 | 0 | 1 |
| Crossroads Group | 15.5 | 0 | 1 |
| Customer Account Data Engine | 15.5 | 0 | 1 |
| Cypress Group | 15.5 | 0 | 1 |
| DLJ Merchant Banking Partners | 15.5 | 0 | 1 |
| Diamond Castle Holdings | 15.5 | 0 | 1 |
| Diamond Castle | 15.5 | 0 | 1 |
| Dominic Shorthouse | 15.5 | 0 | 1 |
| Dubai International Capital | 15.5 | 0 | 1 |
| Early history of private equity | 15.5 | 0 | 1 |
| Electra Private Equity | 15.5 | 0 | 1 |
| Enron Corpus | 15.5 | 0 | 1 |
| Equity International | 15.5 | 0 | 1 |
| private equity firm | 15.5 | 0 | 1 |
| Fenway Partners | 15.5 | 0 | 1 |
| Financial sponsor | 15.5 | 0 | 1 |
| First Reserve Corporation | 15.5 | 0 | 1 |
| Focus Brands | 15.5 | 0 | 1 |
| Forstmann Little & Company | 15.5 | 0 | 1 |
| Fox Paine & Company | 15.5 | 0 | 1 |
| Freeman Spogli & Co. | 15.5 | 0 | 1 |
| Friedman Fleischer & Lowe | 15.5 | 0 | 1 |
| Frontenac Company | 15.5 | 0 | 1 |
| GI Partners | 15.5 | 0 | 1 |
| Gary Reiner | 15.5 | 0 | 1 |
| Genstar Capital | 15.5 | 0 | 1 |
| Global Electronic Party Information Register | 15.5 | 0 | 1 |
| go-to-market strategy | 15.5 | 0 | 1 |
| Leon Black | 15.5 | 0 | 1 |
| Graphite Capital | 15.5 | 0 | 1 |
| Gyrocam Systems | 15.5 | 0 | 1 |
| H.I.G. Capital | 15.5 | 0 | 1 |
| HM Capital Partners | 15.5 | 0 | 1 |
| Hamilton Bradshaw | 15.5 | 0 | 1 |
| Harbour Group Industries | 15.5 | 0 | 1 |
| Harvest Partners | 15.5 | 0 | 1 |
| Heartland Industrial Partners | 15.5 | 0 | 1 |
| HgCapital | 15.5 | 0 | 1 |
| HitQuarters | 15.5 | 0 | 1 |
| Hudson's Bay Trading Company | 15.5 | 0 | 1 |
| private equity fund | 15.5 | 0 | 1 |
| InterMedia Partners | 15.5 | 0 | 1 |
| Irving Place Capital | 15.5 | 0 | 1 |
| J.W. Childs Associates | 15.5 | 0 | 1 |
| JLL Partners | 15.5 | 0 | 1 |
| Jordan Company | 15.5 | 0 | 1 |
| KRG Capital | 15.5 | 0 | 1 |
| Kelso & Company | 15.5 | 0 | 1 |
| Kennet Partners | 15.5 | 0 | 1 |
| Kinderhook Industries | 15.5 | 0 | 1 |
| Kohlberg & Company | 15.5 | 0 | 1 |
| LRG Capital Funds | 15.5 | 0 | 1 |
| Lake Capital | 15.5 | 0 | 1 |
| Lee Equity Partners | 15.5 | 0 | 1 |
| Leeds Equity Partners | 15.5 | 0 | 1 |
| Leonard Green & Partners | 15.5 | 0 | 1 |
| Leopard Capital | 15.5 | 0 | 1 |
| Lightyear Capital | 15.5 | 0 | 1 |
| Lincolnshire Management | 15.5 | 0 | 1 |
| Lindsay Goldberg | 15.5 | 0 | 1 |
| list of private equity firms | 15.5 | 0 | 1 |
| Locust | 15.5 | 0 | 1 |
| M S Banga | 15.5 | 0 | 1 |
| Marc Lasry | 15.5 | 0 | 1 |
| Mark Patterson | 15.5 | 0 | 1 |
| Matrix Partners | 15.5 | 0 | 1 |
| Meritech Capital Partners | 15.5 | 0 | 1 |
| Metalmark Capital | 15.5 | 0 | 1 |
| Michael Chu | 15.5 | 0 | 1 |
| MidOcean Partners | 15.5 | 0 | 1 |
| Mid Europa Partners | 15.5 | 0 | 1 |
| Montagu Private Equity | 15.5 | 0 | 1 |
| Nautic Partners | 15.5 | 0 | 1 |
| North Sea Capital | 15.5 | 0 | 1 |
| Markstone Capital Group | 15.5 | 0 | 1 |
| Novator Partners | 15.5 | 0 | 1 |
| Oak Hill Capital Partners | 15.5 | 0 | 1 |
| Oak Investment Partners | 15.5 | 0 | 1 |
| online lead generation | 15.5 | 0 | 1 |
| OpCapita | 15.5 | 0 | 1 |
| Operating partner | 15.5 | 0 | 1 |
| Pacific Equity Partners | 15.5 | 0 | 1 |
| Pantheon Ventures | 15.5 | 0 | 1 |
| Patron Capital | 15.5 | 0 | 1 |
| persistent object identifier | 15.5 | 0 | 1 |
| Phillip Ean Cohen | 15.5 | 0 | 1 |
| Portfolio company | 15.5 | 0 | 1 |
| Private Equity Analyst | 15.5 | 0 | 1 |
| Private Equity International | 15.5 | 0 | 1 |
| Private Equity Growth Capital Council | 15.5 | 0 | 1 |
| Private Equity News | 15.5 | 0 | 1 |
| Private equity in the 1980s | 15.5 | 0 | 1 |
| Private equity in the 1990s | 15.5 | 0 | 1 |
| Private equity in the 2000s | 15.5 | 0 | 1 |
| Private equity real estate | 15.5 | 0 | 1 |
| Publicly traded private equity | 15.5 | 0 | 1 |
| Quadrangle Group | 15.5 | 0 | 1 |
| quasi-foreign corporation | 15.5 | 0 | 1 |
| Renuka Ramnath | 15.5 | 0 | 1 |
| Resilience Capital Partners | 15.5 | 0 | 1 |
| Rhône Group | 15.5 | 0 | 1 |
| Ridgemont Equity Partners | 15.5 | 0 | 1 |
| Riordan, Lewis & Haden | 15.5 | 0 | 1 |
| Risk Capital Partners | 15.5 | 0 | 1 |
| Riverstone Holdings | 15.5 | 0 | 1 |
| Roark Capital Group | 15.5 | 0 | 1 |
| Robert Knox | 15.5 | 0 | 1 |
| SPPEF | 15.5 | 0 | 1 |
| SVG Capital | 15.5 | 0 | 1 |
| Salida Capital | 15.5 | 0 | 1 |
| Seavi Advent | 15.5 | 0 | 1 |
| Shirley Povich Field | 15.5 | 0 | 1 |
| Silverfleet Capital | 15.5 | 0 | 1 |
| social marketing intelligence | 15.5 | 0 | 1 |
| Stephen Adams | 15.5 | 0 | 1 |
| Stephens Inc. | 15.5 | 0 | 1 |
| Steward Health Care System | 15.5 | 0 | 1 |
| Summit Partners | 15.5 | 0 | 1 |
| Sutter Hill Ventures | 15.5 | 0 | 1 |
| Swarth Group | 15.5 | 0 | 1 |
| TA Associates | 15.5 | 0 | 1 |
| TSG Consumer Partners | 15.5 | 0 | 1 |
| Taxation of private equity and hedge funds | 15.5 | 0 | 1 |
| Thayer Hidden Creek | 15.5 | 0 | 1 |
| The Journal of Private Equity | 15.5 | 0 | 1 |
| Thoma Bravo | 15.5 | 0 | 1 |
| Thomas H. Lee Partners | 15.5 | 0 | 1 |
| Trimaran Capital Partners | 15.5 | 0 | 1 |
| Universal Investment | 15.5 | 0 | 1 |
| Valters un Rapa | 15.5 | 0 | 1 |
| Versa Capital Management | 15.5 | 0 | 1 |
| Vista Equity Partners | 15.5 | 0 | 1 |
| Volkert Doeksen | 15.5 | 0 | 1 |
| Vulcan Capital Management | 15.5 | 0 | 1 |
| Wellspring Capital Management | 15.5 | 0 | 1 |
| Welsh, Carson, Anderson & Stowe | 15.5 | 0 | 1 |
| Weston Presidio | 15.5 | 0 | 1 |
| Willis Stein & Partners | 15.5 | 0 | 1 |
| Wind Point Partners | 15.5 | 0 | 1 |
| Category:History of private equity and venture capital | 15.5 | 0 | 1 |
| Category:Investment banking private equity groups | 15.5 | 0 | 1 |
| Category:Private equity | 15.5 | 0 | 1 |
| Category:Private equity and venture capital investors | 15.5 | 0 | 1 |
| Category:Private equity companies of Jersey | 15.5 | 0 | 1 |
| Category:Private equity companies of Norway | 15.5 | 0 | 1 |
| Category:Private equity firm stubs | 15.5 | 0 | 1 |
| Category:Private equity firms of Asia-Pacific | 15.5 | 0 | 1 |
| Category:Private equity firms by country | 15.5 | 0 | 1 |
| Category:Private equity firms of Australia | 15.5 | 0 | 1 |
| Category:Private equity firms of Bermuda | 15.5 | 0 | 1 |
| Category:Private equity firms of Brazil | 15.5 | 0 | 1 |
| Category:Private equity firms of Canada | 15.5 | 0 | 1 |
| Category:Private equity firms of China | 15.5 | 0 | 1 |
| Category:Private equity firms of Europe | 15.5 | 0 | 1 |
| Category:Private equity firms of Greece | 15.5 | 0 | 1 |
| Category:Private equity firms of Hong Kong | 15.5 | 0 | 1 |
| Category:Private equity firms of Russia | 15.5 | 0 | 1 |
| Category:Private equity firms of Sweden | 15.5 | 0 | 1 |
| Category:Private equity firms of Switzerland | 15.5 | 0 | 1 |
| Category:Private equity firms of Vietnam | 15.5 | 0 | 1 |
| Category:Private equity firms of the Middle East | 15.5 | 0 | 1 |
| Category:Private equity firms of the United Kingdom | 15.5 | 0 | 1 |
| Category:Private equity firms of the United States | 15.5 | 0 | 1 |
| Category:Private equity media and publications | 15.5 | 0 | 1 |
| Category:Private equity secondary market | 15.5 | 0 | 1 |
| Category:Private equity stubs | 15.5 | 0 | 1 |
| Category:United States private equity firm stubs | 15.5 | 0 | 1 |
| Category:WikiProject Private Equity Task Force participants | 15.5 | 0 | 1 |
| Category:Private equity firms | 15.5 | 0 | 1 |
| Category:Private equity firms of France | 15.5 | 0 | 1 |
| Q10286490 | 15.5 | 0 | 1 |
| Q10655823 | 15.5 | 0 | 1 |
| Triton Partners | 15.5 | 0 | 1 |
| Q11689153 | 15.5 | 0 | 1 |
| Capman | 15.5 | 0 | 1 |
| Suomen Teollisuussijoitus Oy | 15.5 | 0 | 1 |
| HitecVision | 15.5 | 0 | 1 |
| Axcel | 15.5 | 0 | 1 |
| Deltaq | 15.5 | 0 | 1 |
| 3TS Capital Partners | 15.5 | 0 | 1 |
| GED Private Equity | 15.5 | 0 | 1 |
| Innova Capital | 15.5 | 0 | 1 |
| Q12733314 | 15.5 | 0 | 1 |
| Category:Private equity firm logos | 15.5 | 0 | 1 |
| Category:Private equity firms of Latin America | 15.5 | 0 | 1 |
| Category:WikiProject Private Equity Task Force | 15.5 | 0 | 1 |
| Category:WikiProject Private Equity Articles | 15.5 | 0 | 1 |
| Template:Private equity and venture capital | 15.5 | 0 | 1 |
| Tomasz Czechowicz | 15.5 | 0 | 1 |
| Vision Capital | 15.5 | 0 | 1 |
| Ardian | 15.5 | 0 | 1 |
| Category:Private equity biography stubs | 15.5 | 0 | 1 |
| Category:Private equity firms based in Washington, D.C. | 15.5 | 0 | 1 |
| Category:Private equity firms of Cambodia | 15.5 | 0 | 1 |
| Category:Private equity firms of Denmark | 15.5 | 0 | 1 |
| Category:Private equity firms of Haiti | 15.5 | 0 | 1 |
| Category:Private equity firms of the Netherlands | 15.5 | 0 | 1 |
| Private equity secondary market | 15.5 | 0 | 1 |
| International Journal of Business Forecasting and Market Intelligence | 15.5 | 0 | 1 |
| Marketing Intelligence Planning | 15.5 | 0 | 1 |
| International Journal of Business Data Communications and Networking | 15.5 | 0 | 1 |
| China Media Capital | 15.5 | 0 | 1 |
| Madison Dearborn Partners | 15.5 | 0 | 1 |
| Accel-KKR | 15.5 | 0 | 1 |
| Abu Dhabi United Group | 15.5 | 0 | 1 |
| history of private equity and venture capital | 15.5 | 0 | 1 |
| Yucaipa Companies | 15.5 | 0 | 1 |
| Brian Pokorny | 15.5 | 0 | 1 |
| royalty fund | 15.5 | 0 | 1 |
| Bregal Sagemount | 15.5 | 0 | 1 |
| Vitruvian Partners | 15.5 | 0 | 1 |
| Synova Capital | 15.5 | 0 | 1 |
| Berkshire Partners | 15.5 | 0 | 1 |
| EnCap Investments | 15.5 | 0 | 1 |
| HarbourVest Partners | 15.5 | 0 | 1 |
| Phoenix Equity Partners | 15.5 | 0 | 1 |
| TheOfficialBoard | 15.5 | 0 | 1 |
| Georgian Co-Investment Fund | 15.5 | 0 | 1 |
| Olympus Partners | 15.5 | 0 | 1 |
| Wesray Capital Corporation | 15.5 | 0 | 1 |
| Column Five | 15.5 | 0 | 1 |
| Spell Capital Partners | 15.5 | 0 | 1 |
| Goldman Sachs Capital Partners | 15.5 | 0 | 1 |
| Trilantic Capital Partners | 15.5 | 0 | 1 |
| Opus Capital | 15.5 | 0 | 1 |
| Sales intelligence | 15.5 | 0 | 1 |
| New Silk Route | 15.5 | 0 | 1 |
| Public Market Equivalent | 15.5 | 0 | 1 |
| Japan Industrial Partners | 15.5 | 0 | 1 |
| Ming-Po Cai | 15.5 | 0 | 1 |
| AnaCap Financial Partners | 15.5 | 0 | 1 |
| CapitalG | 15.5 | 0 | 1 |
| Active Owners Denmark | 15.5 | 0 | 1 |
| Quadria Capital | 15.5 | 0 | 1 |
| Distribution Waterfall | 15.5 | 0 | 1 |
| Shanghai Venture Capital Co. | 15.5 | 0 | 1 |
| Pension investment in private equity | 15.5 | 0 | 1 |
| Tetragon Financial Group | 15.5 | 0 | 1 |
| Rede Partners | 15.5 | 0 | 1 |
| Capital commitment | 15.5 | 0 | 1 |
| GFH Capital | 15.5 | 0 | 1 |
| KPS Capital Partners | 15.5 | 0 | 1 |
| Mansford | 15.5 | 0 | 1 |
| Hillhouse Capital | 15.5 | 0 | 1 |
| Auldbrass Partners | 15.5 | 0 | 1 |
| Richard M. Powell | 15.5 | 0 | 1 |
| Hambro Magan | 15.5 | 0 | 1 |
| Hutton Collins | 15.5 | 0 | 1 |
| Hony Capital | 15.5 | 0 | 1 |
| Ashish Dhawan | 15.5 | 0 | 1 |
| Template:User Private Equity Taskforce | 15.5 | 0 | 1 |
| Lativan Public Service Media | 15.5 | 0 | 1 |
| Stephen P. Murray | 15.5 | 0 | 1 |
| Art Wrubel | 15.5 | 0 | 1 |
| John Grayken | 15.5 | 0 | 1 |
| J&T Private Equity Group | 15.5 | 0 | 1 |
| Americans for Financial Reform | 15.5 | 0 | 1 |
| Kildare Partners | 15.5 | 0 | 1 |
| Sun Capital Partners UK | 15.5 | 0 | 1 |
| TDR Capital | 15.5 | 0 | 1 |
| Ekuinas | 15.5 | 0 | 1 |
| Template:Largest private equity firms | 15.5 | 0 | 1 |
| Quantum Capital Group | 15.5 | 0 | 1 |
| Grovepoint Capital | 15.5 | 0 | 1 |
| WikiProject Private Equity | 15.5 | 0 | 1 |
| UK Private Capital | 15.5 | 0 | 1 |
| Council Capital | 15.5 | 0 | 1 |
| Blackstreet Capital Management | 15.5 | 0 | 1 |
| I Squared Capital | 15.5 | 0 | 1 |
| ECI Partners | 15.5 | 0 | 1 |
| HarbourVest Global Private Equity | 15.5 | 0 | 1 |
| George A. Bitar | 15.5 | 0 | 1 |
| Paragon Partners | 15.5 | 0 | 1 |
| Template:Private equity firms | 15.5 | 0 | 1 |
| Template:Private equity investors | 15.5 | 0 | 1 |
| Template:History of private equity and venture capital | 15.5 | 0 | 1 |
| Template:Merchant banking private equity groups | 15.5 | 0 | 1 |
| Fondinvest Capital | 15.5 | 0 | 1 |
| Data onboarding | 15.5 | 0 | 1 |
| Livingbridge | 15.5 | 0 | 1 |
| Michael Reinstein | 15.5 | 0 | 1 |
| Bert Wiegman | 15.5 | 0 | 1 |
| Frazier Healthcare Partners | 15.5 | 0 | 1 |
| TPH Partners | 15.5 | 0 | 1 |
| Langholm Capital | 15.5 | 0 | 1 |
| Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review | 15.5 | 0 | 1 |
| Transferred Account Data Interchange Group Code | 15.5 | 0 | 1 |
| Seasonality and children's blood lead levels: developing a predictive model using climatic variables and blood lead data from Indianapolis, Indiana, Syracuse, New York, and New Orleans, Louisiana (USA). | 15.5 | 0 | 1 |
| Category:Private equity firms of Singapore | 15.5 | 0 | 1 |
| Nexus Group | 15.5 | 0 | 1 |
| Huron Capital Partners | 15.5 | 0 | 1 |
| Atlante | 15.5 | 0 | 1 |
| Djinn Lite: a tool for customised gene transcript modelling, annotation-data enrichment and exploration | 15.5 | 0 | 1 |
| Tanzanian Private Equity Association | 15.5 | 0 | 1 |
| Category:Private equity firms of Malaysia | 15.5 | 0 | 1 |
| Category:Private equity companies of South Africa | 15.5 | 0 | 1 |
| Template:WikiProject Private Equity | 15.5 | 0 | 1 |
| Deutsche Cannabis | 15.5 | 0 | 1 |
| Target engagement in lead generation | 15.5 | 0 | 1 |
| Q26833777 | 15.5 | 0 | 1 |
| Corpfin Capital | 15.5 | 0 | 1 |
| Novel allosteric sites on Ras for lead generation | 15.5 | 0 | 1 |
| Discovery of a novel warhead against beta-secretase through fragment-based lead generation | 15.5 | 0 | 1 |
| Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency | 15.5 | 0 | 1 |
| Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design | 15.5 | 0 | 1 |
| Structure Guided Development of Novel Thymidine Mimetics Targeting Pseudomonas aeruginosa Thymidylate Kinase: From Hit to Lead Generation | 15.5 | 0 | 1 |
| Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation | 15.5 | 0 | 1 |
| Incidence and Reproduction Numbers of Pertussis: Estimates from Serological and Social Contact Data in Five European Countries | 15.5 | 0 | 1 |
| De novo fragment design: a medicinal chemistry approach to fragment-based lead generation | 15.5 | 0 | 1 |
| Structure Guided Lead Generation for M. tuberculosis Thymidylate Kinase (Mtb TMK): Discovery of 3-Cyanopyridone and 1,6-Naphthyridin-2-one as Potent Inhibitors | 15.5 | 0 | 1 |
| Fragment Screening of Soluble Epoxide Hydrolase for Lead Generation—Structure‐Based Hit Evaluation and Chemistry Exploration | 15.5 | 0 | 1 |
| Hit and lead generation: beyond high-throughput screening | 15.5 | 0 | 1 |
| Caribbean Catastrophe Risk Insurance Facility Segregated Portfolio Company | 15.5 | 0 | 1 |
| Facts, figures and trends in lead generation | 15.5 | 0 | 1 |
| Computational chemistry-driven decision making in lead generation | 15.5 | 0 | 1 |
| A Bayesian Approach to the Overlap Analysis of Epidemiologically Linked Traits | 15.5 | 0 | 1 |
| Zelnick Media Capital | 15.5 | 0 | 1 |
| Stirling Square Capital Partners | 15.5 | 0 | 1 |
| Japonica Partners | 15.5 | 0 | 1 |
| Northern International Trust Co., Ltd. | 15.5 | 0 | 1 |
| Palamon Capital Partners | 15.5 | 0 | 1 |
| Creating Novel Activated Factor XI Inhibitors through Fragment Based Lead Generation and Structure Aided Drug Design | 15.5 | 0 | 1 |
| Asante Capital | 15.5 | 0 | 1 |
| French Private Equity Association | 15.5 | 0 | 1 |
| The Economics of Private Equity Funds | 15.5 | 0 | 1 |
| Molecular recognition: the fragment approach in lead generation | 15.5 | 0 | 1 |
| The safety of oseltamivir in pregnancy: an updated review of post-marketing data | 15.5 | 0 | 1 |
| An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes | 15.5 | 0 | 1 |
| Strategies for conducting ADME studies during lead generation in the drug discovery process | 15.5 | 0 | 1 |
| Efficient assessment of exposure to manual lifting using company data | 15.5 | 0 | 1 |
| The trial of business data analysis at the Department of Radiology by constructing the auto-regressive integrated moving-average (ARIMA) model | 15.5 | 0 | 1 |
| Large-scale reconstruction of 3D structures of human chromosomes from chromosomal contact data | 15.5 | 0 | 1 |
| Keep research reports from collecting dust. Cooperation leads to effective marketing data | 15.5 | 0 | 1 |
| How pre-marketing data can be used for predicting the weight of drug interactions in clinical practice. | 15.5 | 0 | 1 |
| High-quality genome (re)assembly using chromosomal contact data | 15.5 | 0 | 1 |
| Non-contact data access with direction identification for industrial differential serial bus | 15.5 | 0 | 1 |
| Addressing the deficiencies in the evidence-base for primary practice in regional Australia - sentinel practices data sourcing (SPDS) project: a pilot study | 15.5 | 0 | 1 |
| High-throughput docking for lead generation | 15.5 | 0 | 1 |
| Enhancing the evaluation of pathogen transmission risk in a hospital by merging hand-hygiene compliance and contact data: a proof-of-concept study | 15.5 | 0 | 1 |
| The contribution of combinatorial chemistry to lead generation: an interim analysis | 15.5 | 0 | 1 |
| Integrating machine learning techniques into robust data enrichment approach and its application to gene expression data | 15.5 | 0 | 1 |
| The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. | 15.5 | 0 | 1 |
| NMR techniques for characterization of ligand binding: utility for lead generation and optimization in drug discovery | 15.5 | 0 | 1 |
| Using data from patient interactions in primary care for population level chronic disease surveillance: The Sentinel Practices Data Sourcing (SPDS) project | 15.5 | 0 | 1 |
| Applying data mining techniques to library design, lead generation and lead optimization | 15.5 | 0 | 1 |
| Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials. | 15.5 | 0 | 1 |
| Incorporating social contact data in spatio-temporal models for infectious disease spread | 15.5 | 0 | 1 |
| The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative | 15.5 | 0 | 1 |
| A retrospective study of acute mountain sickness on Mt. Kilimanjaro using trekking company data. | 15.5 | 0 | 1 |
| A simple improved triangular reference frame for determination of frontal plane vector angles from limb lead data | 15.5 | 0 | 1 |
| Combining high-resolution contact data with virological data to investigate influenza transmission in a tertiary care hospital | 15.5 | 0 | 1 |
| Detailed contact data and the dissemination of Staphylococcus aureus in hospitals | 15.5 | 0 | 1 |
| Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data | 15.5 | 0 | 1 |
| Iterative reconstruction of three-dimensional models of human chromosomes from chromosomal contact data | 15.5 | 0 | 1 |
| Library design practices for success in lead generation with small molecule libraries | 15.5 | 0 | 1 |
| Non-stochastic quadratic fingerprints and LDA-based QSAR models in hit and lead generation through virtual screening: theoretical and experimental assessment of a promising method for the discovery of new antimalarial compounds. | 15.5 | 0 | 1 |
| Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data | 15.5 | 0 | 1 |
| Drug-company data and the public interest | 15.5 | 0 | 1 |
| Getting your game on with business data | 15.5 | 0 | 1 |
| Fast and Efficient Fragment-Based Lead Generation by Fully Automated Processing and Analysis of Ligand-Observed NMR Binding Data | 15.5 | 0 | 1 |
| Invited commentary: Challenges of using contact data to understand acute respiratory disease transmission | 15.5 | 0 | 1 |
| Visualizing business data with generalized treemaps | 15.5 | 0 | 1 |
| Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data | 15.5 | 0 | 1 |
| Prediction of long-term and frequent sickness absence using company data | 15.5 | 0 | 1 |
| An analysis of the impact of LHC Run I proton-lead data on nuclear parton densities | 15.5 | 0 | 1 |
| Combining medical information with a business data system | 15.5 | 0 | 1 |
| Assay of D-lactate in urine of infants and children with reference values taking into account data below detection limit | 15.5 | 0 | 1 |
| Comparative assessment of the WHO and Gilson histological classifications of prostatic neoplasms (taking into account data of ploidy studies) | 15.5 | 0 | 1 |
| [Use of blood lead data to evaluate and prevent childhood lead poisoning in Latin America]. | 15.5 | 0 | 1 |
| Components of successful lead generation | 15.5 | 0 | 1 |
| Computational chemistry as an integral component of lead generation | 15.5 | 0 | 1 |
| Improving success rates for lead generation using affinity binding technologies | 15.5 | 0 | 1 |
| Application and utilization of chemoinformatics tools in lead generation and optimization | 15.5 | 0 | 1 |
| Median-based overlap analysis for single case data: a second study | 15.5 | 0 | 1 |
| Disparities in hospital utilization in an urban county: use of local consumer marketing data for priority setting | 15.5 | 0 | 1 |
| Testing the mean for dependent business data | 15.5 | 0 | 1 |
| Electron density guided fragment-based drug design--a lead generation example | 15.5 | 0 | 1 |
| Unused information: detecting and applying eye contact data in computerized healthcare systems | 15.5 | 0 | 1 |
| Using empirical social contact data to model person to person infectious disease transmission: an illustration for varicella | 15.5 | 0 | 1 |
| Decision support methods for the detection of adverse events in post-marketing data | 15.5 | 0 | 1 |
| Improved data retrieval from TreeBASE via taxonomic and linguistic data enrichment | 15.5 | 0 | 1 |
| Marketing data: has the rise of impact factor led to the fall of objective language in the scientific article? | 15.5 | 0 | 1 |
| Fragment-based lead generation: identification of seed fragments by a highly efficient fragment screening technology | 15.5 | 0 | 1 |
| Review of the ICD Registry's third year, expansion to include lead data and pediatric ICD procedures, and role for measuring performance | 15.5 | 0 | 1 |
| Review of the registry's fourth year, incorporating lead data and pediatric ICD procedures, and use as a national performance measure. | 15.5 | 0 | 1 |
| Robust and accurate data enrichment statistics via distribution function of sum of weights. | 15.5 | 0 | 1 |
| Insights into Integrated Lead Generation and Target Identification in Malaria and Tuberculosis Drug Discovery | 15.5 | 0 | 1 |
| Nuclear magnetic resonance-based approaches for lead generation in drug discovery. | 15.5 | 0 | 1 |
| Ligand identification for G-protein-coupled receptors: a lead generation perspective | 15.5 | 0 | 1 |
| Accuracy of protein allergenicity prediction can be improved by taking into account data on allergenic protein discontinuous peptides | 15.5 | 0 | 1 |
| Strategies for the generation, validation and application of in silico ADMET models in lead generation and optimization. | 15.5 | 0 | 1 |
| Life in the fast lane: high-throughput chemistry for lead generation and optimisation | 15.5 | 0 | 1 |
| Thrive or survive: will new health plan IT needs spur vendor consolidation? | 15.5 | 0 | 1 |
| Binding sites analyser (BiSA): software for genomic binding sites archiving and overlap analysis | 15.5 | 0 | 1 |
| Predicting Epidemic Risk from Past Temporal Contact Data | 15.5 | 0 | 1 |
| Assessing the likely effectiveness of multispecies management for imperiled desert fishes with niche overlap analysis. | 15.5 | 0 | 1 |
| New lead generation strategies for protein kinase inhibitors - fragment based screening approaches | 15.5 | 0 | 1 |
| Transforming the TGFbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TbetaRI (ALK5). | 15.5 | 0 | 1 |
| An improved model for fragment-based lead generation at AstraZeneca | 15.5 | 0 | 1 |
| Nurse staffing and deficiencies in the largest for-profit nursing home chains and chains owned by private equity companies | 15.5 | 0 | 1 |
| Quantifying the foodscape: A systematic review and meta-analysis of the validity of commercially available business data | 15.5 | 0 | 1 |
| Private equity investment in health care companies: eleven steps to an effective health care regulatory diligence review | 15.5 | 0 | 1 |
| Data management and data enrichment for systems biology projects | 15.5 | 0 | 1 |
| The Silverfern Group | 15.5 | 0 | 1 |
| Optimization of frontal-plane electrocardiographic lead data in the 30° hexaxial system | 15.5 | 0 | 1 |
| Methods for diversity and overlap analysis in T-cell receptor populations | 15.5 | 0 | 1 |
| Visual determination of projections of the cardiac vector on the frontal, sagittal and horizontal planes according to orthogonal lead data | 15.5 | 0 | 1 |
| Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective | 15.5 | 0 | 1 |
| An analysis of blood lead data in clinical records by external data on lead pipes and age of household. | 15.5 | 0 | 1 |
| Fairness opinions in health care transactions--cause and effect: the emergence of private equity funds as a driving force in big and small transactions and the resulting increased use of fairness opinions | 15.5 | 0 | 1 |
| Improving lead generation success through integrated methods: transcending 'drug discovery by numbers' | 15.5 | 0 | 1 |
| Exploring the Relationship between Private Equity Ownership and Nursing Home Performance: A Review | 15.5 | 0 | 1 |
| The role of evidence in humanitarian assessment: the Seed System Security Assessment and the Emergency Market Mapping and Analysis | 15.5 | 0 | 1 |
| Neoclassic drug discovery: the case for lead generation using phenotypic and functional approaches | 15.5 | 0 | 1 |
| Financialisation in health care: An analysis of private equity fund investments in Turkey | 15.5 | 0 | 1 |
| Functional classification of genes using semantic distance and fuzzy clustering approach: evaluation with reference sets and overlap analysis. | 15.5 | 0 | 1 |
| Privileged scaffolds in lead generation | 15.5 | 0 | 1 |
| Estimating the epidemic risk using non-uniformly sampled contact data | 15.5 | 0 | 1 |
| A comprehensive company database analysis of biological assay variability | 15.5 | 0 | 1 |
| Lead generation in crop protection research: a portfolio approach to agrochemical discovery | 15.5 | 0 | 1 |
| Bioisosteric Replacement and Scaffold Hopping in Lead Generation and Optimization | 15.5 | 0 | 1 |
| Dual-acting of Hybrid Compounds - A New Dawn in the Discovery of Multi-target Drugs: Lead Generation Approaches. | 15.5 | 0 | 1 |
| Sycamore Partners | 15.5 | 0 | 1 |
| Inhibition of Hypoxia‐Induced Gene Transcription by Substituted Pyrazolyl Oxadiazoles: Initial Lead Generation and Structure–Activity Relationships | 15.5 | 0 | 1 |
| Warwick Energy Group | 15.5 | 0 | 1 |
| Identification of 2-anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation | 15.5 | 0 | 1 |
| Canyon Bridge Capital Partners | 15.5 | 0 | 1 |
| Creation of Novel Cores for β-Secretase (BACE-1) Inhibitors: A Multiparameter Lead Generation Strategy | 15.5 | 0 | 1 |
| Lizard assemblage from a sand dune habitat from southeastern Brazil: a niche overlap analysis | 15.5 | 0 | 1 |
| If private equity sized up your business. | 15.5 | 0 | 1 |
| Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation | 15.5 | 0 | 1 |
| Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective | 15.5 | 0 | 1 |
| Benchmark Outcomes for Pulmonary Valve Replacement Using The Society of Thoracic Surgeons Databases | 15.5 | 0 | 1 |
| Market mapping: a guide to the future | 15.5 | 0 | 1 |
| Wolfgang Reichenberger | 15.5 | 0 | 1 |
| Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis | 15.5 | 0 | 1 |
| Exploring the role of human miRNAs in virus–host interactions using systematic overlap analysis | 15.5 | 0 | 1 |
| The evaluation of antibiotic prescribing in general practice using a health insurance company database: penicillins use. | 15.5 | 0 | 1 |
| Can private equity deliver on equity? | 15.5 | 0 | 1 |
| Wharf Real Estate Investment Company Limited | 15.5 | 0 | 1 |
| Lead generation and optimization based on protein-ligand complementarity. | 15.5 | 0 | 1 |
| Federico Bravo | 15.5 | 0 | 1 |
| Design, syntheses, and structure-activity relationships of indan derivatives as endothelin antagonists; new lead generation of non-peptidic antagonist from peptidic leads | 15.5 | 0 | 1 |
| Cell permeability as a parameter for lead generation in the protein Tyrosine kinase inhibition field | 15.5 | 0 | 1 |
| Novel Lead Generation through Hypothetical Pharmacophore Three-Dimensional Database Searching: Discovery of Isoflavonoids as Nonsteroidal Inhibitors of Rat 5α-Reductase | 15.5 | 0 | 1 |
| Private equity ownership and nursing home financial performance | 15.5 | 0 | 1 |
| Stamina Private Equity Investments | 15.5 | 0 | 1 |
| Is Computer-Assisted Rescaffolding the Future in Lead Generation? | 15.5 | 0 | 1 |
| In Silico-Screening Approaches for Lead Generation: Identification of Novel Allosteric Modulators of Human-Erythrocyte Pyruvate Kinase | 15.5 | 0 | 1 |
| Ligand based lead generation - considering chemical accessibility in rescaffolding approaches via BROOD. | 15.5 | 0 | 1 |
| A novel method of protein secondary structure prediction with high segment overlap measure: support vector machine approach | 15.5 | 0 | 1 |
| The lead generation of protein tyrosine kinase inhibitors by quantitative structure-activity relationship analysis | 15.5 | 0 | 1 |
| What Happens to a Nursing Home Chain When Private Equity Takes Over? A Longitudinal Case Study | 15.5 | 0 | 1 |
| Dermatology Practice Consolidation Fueled by Private Equity Investment: Potential Consequences for the Specialty and Patients | 15.5 | 0 | 1 |
| Lead generation using pharmacophore mapping and three-dimensional database searching: application to muscarinic M(3) receptor antagonists | 15.5 | 0 | 1 |
| Quantum Growth Ventures | 15.5 | 0 | 1 |
| RFC 3335: MIME-based Secure Peer-to-Peer Business Data Interchange over the Internet | 15.5 | 0 | 1 |
| RFC 4130: MIME-Based Secure Peer-to-Peer Business Data Interchange Using HTTP, Applicability Statement 2 (AS2) | 15.5 | 0 | 1 |
| RFC 4823: FTP Transport for Secure Peer-to-Peer Business Data Interchange over the Internet | 15.5 | 0 | 1 |
| Tapping private equity. More providers hope to join the party | 15.5 | 0 | 1 |
| Adjusting for selective non-participation with re-contact data in the FINRISK 2012 survey | 15.5 | 0 | 1 |
| What investors are looking for. More private equity is coming into the market, but what do investors want? | 15.5 | 0 | 1 |
| What does the MADRS mean? Equipercentile linking with the CGI using a company database of mirtazapine studies | 15.5 | 0 | 1 |
| Private equity firms are invited to get involved with commissioning | 15.5 | 0 | 1 |
| Creador | 15.5 | 0 | 1 |
| WL Ross & Co | 15.5 | 0 | 1 |
| MHR Fund Management | 15.5 | 0 | 1 |
| Idinvest Partners | 15.5 | 0 | 1 |
| Aberdeen Private Equity | 15.5 | 0 | 1 |
| Pacific Fertility Center | 15.5 | 0 | 1 |
| Does Individual Gambling Behavior Vary across Gambling Venues with Differing Numbers of Terminals? An Empirical Real-World Study using Player Account Data | 15.5 | 0 | 1 |
| GfK Marketing Intelligence Review | 15.5 | 0 | 1 |
| Use of a health insurance company database for study of theoretical exposure to hypolipidemic agents | 15.5 | 0 | 1 |
| Tagged fragment method for evolutionary structure-based de novo lead generation and optimization | 15.5 | 0 | 1 |
| Identification of novel 1,2,3,6-tetrahydropyridyl-substituted benzo[d]thiazoles: Lead generation and optimization toward potent and orally active EP1 receptor antagonists | 15.5 | 0 | 1 |
| ON-FIELD EVALUATION OF OPERATOR LENS PROTECTIVE DEVICES IN INTERVENTIONAL RADIOLOGY. | 15.5 | 0 | 1 |
| Deaths in children with acute dehydration: learning from a nationwide medical insurance company database | 15.5 | 0 | 1 |
| Bloomberg private company database | 15.5 | 0 | 1 |
| Structure Guided Lead Generation toward Nonchiral M. tuberculosis Thymidylate Kinase Inhibitors | 15.5 | 0 | 1 |
| Opening the lead generation toolbox | 15.5 | 0 | 1 |
| When seconds count. EDIS radar screens show increased demand, integration and vendor consolidation. | 15.5 | 0 | 1 |
| Finance. Uncertainty around reform gives pause to private equity investors | 15.5 | 0 | 1 |
| Confirmation of usefulness of a structure construction program based on three-dimensional receptor structure for rational lead generation | 15.5 | 0 | 1 |
| A maximum likelihood algorithm for reconstructing 3D structures of human chromosomes from chromosomal contact data | 15.5 | 0 | 1 |
| CEP Invest Private Equity, | 15.5 | 0 | 1 |
| Searchlight Capital | 15.5 | 0 | 1 |
| Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example | 15.5 | 0 | 1 |
| SOV_refine: A further refined definition of segment overlap score and its significance for protein structure similarity | 15.5 | 0 | 1 |
| Archer Capital | 15.5 | 0 | 1 |
| Endless (private equity) | 15.5 | 0 | 1 |
| Lovell Minnick Partners | 15.5 | 0 | 1 |
| Quadrant Private Equity | 15.5 | 0 | 1 |
| Hosein Khajeh-Hosseiny | 15.5 | 0 | 1 |
| Category:Softbank portfolio companies | 15.5 | 0 | 1 |
| Private Equity Performance: Returns, Persistence, and Capital Flows | 15.5 | 0 | 1 |
| Using the 7Ps as a generic marketing mix | 15.5 | 0 | 1 |
| The economics of small business finance: The roles of private equity and debt markets in the financial growth cycle | 15.5 | 0 | 1 |
| Bridge Growth Partners | 15.5 | 0 | 1 |
| Intera Partners | 15.5 | 0 | 1 |
| Abalena Capital Limited | 15.5 | 0 | 1 |
| High-resolution epidemic simulation using within-host infection and contact data | 15.5 | 0 | 1 |
| Crowding out private equity: Canadian evidence | 15.5 | 0 | 1 |
| Holland Private Equity | 15.5 | 0 | 1 |
| Genesis Private Equity Fund III | 15.5 | 0 | 1 |
| Q56753197 | 15.5 | 0 | 1 |
| Ability of crime, demographic and business data to forecast areas of increased violence | 15.5 | 0 | 1 |
| The consequences of private equity acquisitions for employees: new evidence on the impact on wages, employment and productivity | 15.5 | 0 | 1 |
| The employment consequences of private equity acquisitions: The case of institutional buy outs | 15.5 | 0 | 1 |
| Private Equity Acquisitions of Continental European Firms: the Impact of Ownership and Control on the Likelihood of Being Taken Private | 15.5 | 0 | 1 |
| Private Equity Acquisitions of Continental European Firms: the Impact of Ownership and Control on the Likelihood of Being Taken Private | 15.5 | 0 | 1 |
| Private Equity Takeovers and Employment in the UK: Some Empirical Evidence | 15.5 | 0 | 1 |
| Use of Best Practice Strategies to Improve Longitudinal Study Participation: Analysis of Telephone Contact Data From the Northwest Regional Burn Model System | 15.5 | 0 | 1 |
| Smartland | 15.5 | 0 | 1 |
| Future considerations for clinical dermatology in the setting of 21 century American policy reform: corporatization and the rise of private equity in dermatology | 15.5 | 0 | 1 |
| The role of pollution versus natural geological sources for lead enrichment in recent lake sediments and surface forest soils | 15.5 | 0 | 1 |
| The Public Market Equivalent and Private Equity Performance | 15.5 | 0 | 1 |
| Identification of Novel Non-nucleoside Reverse Transcriptase Inhibitors Using Fragment-based Lead Generation | 15.5 | 0 | 1 |
| Brand strategies in social media | 15.5 | 0 | 1 |
| Can Marketing Data Aid Survey Research? Examining Accuracy and Completeness in Consumer-File Data | 15.5 | 0 | 1 |
| Private equity and human resource management: An emerging agenda | 15.5 | 0 | 1 |
| Private equity: A review and synthesis | 15.5 | 0 | 1 |
| What do venture capital and private equity firms do? Some current and historical examples | 15.5 | 0 | 1 |
| Classification of Bank Direct Marketing Data Using Subsets of Training Data | 15.5 | 0 | 1 |
| New Modalities, Technologies, and Partnerships in Probe and Lead Generation: Enabling a Mode-of-Action Centric Paradigm | 15.5 | 0 | 1 |
| Private equity ownership and nursing home quality: an instrumental variables approach | 15.5 | 0 | 1 |
| A game theory approach to online lead generation for oligopoly markets | 15.5 | 0 | 1 |
| Perverse incentives of special purpose acquisition companies, the “poor man's private equity funds” | 15.5 | 0 | 1 |
| Corporate venture capital and the balance of risks and rewards for portfolio companies | 15.5 | 0 | 1 |
| Private Equity and the Public Good | 15.5 | 0 | 1 |
| The possibility of critique under a financialized capitalism: The case of private equity in the United Kingdom | 15.5 | 0 | 1 |
| Can using geographical factors leverage private equity to deliver sustainable development results? | 15.5 | 0 | 1 |
| The macroeconomic determinants of private equity investment: a European comparison | 15.5 | 0 | 1 |
| Benchmark Outcomes in Supported Employment | 15.5 | 0 | 1 |
| Board Interlock or Private Equity Funding? How Brazilian Pre-IPO Firms Signal Management Quality | 15.5 | 0 | 1 |
| Country of Origin Effects and New Financial Actors: Private Equity Investment and Work and Employment Practices of French Firms | 15.5 | 0 | 1 |
| The Impact of Private Equity on Employment: The Consequences of Fund Country of Origin-New Evidence from France | 15.5 | 0 | 1 |
| The role of domestic and cross-border venture capital investors in the growth of portfolio companies | 15.5 | 0 | 1 |
| Changing the Business Model: Effects of Venture Capital Firms and Outside CEOs on Portfolio Company Performance | 15.5 | 0 | 1 |
| Morphing: The Linkage of Inward Private Equity and Outward Ventures | 15.5 | 0 | 1 |
| Habit, aggregation and long memory: evidence from television audience data | 15.5 | 0 | 1 |
| Correlates of record linkage and estimating risks of non-linkage biases in business data sets | 15.5 | 0 | 1 |
| Penta Investments Group Limited | 15.5 | 0 | 1 |
| Irritable bowel syndrome, gastro-oesophageal reflux disease and dyspepsia: Overlap analysis using loglinear models | 15.5 | 0 | 1 |
| HBIM TO VR. SEMANTIC AWARENESS AND DATA ENRICHMENT INTEROPERABILITY FOR PARAMETRIC LIBRARIES OF HISTORICAL ARCHITECTURE | 15.5 | 0 | 1 |
| Knowledge-based data enrichment for HBIM: Exploring high-quality models using the semantic-web | 15.5 | 0 | 1 |
| Journal Overlap Analysis of the GeoRef and Web of Science Databases | 15.5 | 0 | 1 |
| A Review of “The Directory of Venture Capital and Private Equity Firms: Domestic and International” | 15.5 | 0 | 1 |
| Private Equity and the Entrepreneur | 15.5 | 0 | 1 |
| Special issue on private equity and venture capital topics | 15.5 | 0 | 1 |
| Venturing forth: Venture capital and private equity information in academic business libraries | 15.5 | 0 | 1 |
| The ABCs of private equity and venture capital data and information | 15.5 | 0 | 1 |
| The directory of venture capital & private equity firms (20th Ed.) | 15.5 | 0 | 1 |
| Private equity fund investment due diligence | 15.5 | 0 | 1 |
| Pratt's guide to private equity & venture capital sources | 15.5 | 0 | 1 |
| Selected Bibliographic Guide to Canadian Business Data | 15.5 | 0 | 1 |
| The evolution of private equity: corporate restructuring in the UK,c.1945–2010 | 15.5 | 0 | 1 |
| An Overlap Analysis of Occupational Therapy Electronic Journals Available in Full-text Databases and Subscription Services | 15.5 | 0 | 1 |
| Fragment-Based Lead Generation of 5-Phenyl-1-pyrazole-3-carboxamide Derivatives as Leads for Potent Factor Xia Inhibitors | 15.5 | 0 | 1 |
| Experimental evidence for the origin of lead enrichment in convergent-margin magmas | 15.5 | 0 | 1 |
| Modeling and Querying Business Data with Artifact Lifecycle | 15.5 | 0 | 1 |
| The dynamics of sport marketing | 15.5 | 0 | 1 |
| Future research directions in tourism marketing | 15.5 | 0 | 1 |
| High-Resolution Epidemic Simulation Using Within-Host Infection and Contact Data | 15.5 | 0 | 1 |
| Refocusing marketing to reflect practice | 15.5 | 0 | 1 |
| Angular-overlap analysis of the iron(II) site in [2Fe-2S] clusters | 15.5 | 0 | 1 |
| Presenting Business Data | 15.5 | 0 | 1 |
| Taxation of Hedge Fund and Private Equity Managers | 15.5 | 0 | 1 |
| Legislation to Repeal the Private Equity Fund Adviser Registration Requirement in the Dodd-Frank Act: In Brief | 15.5 | 0 | 1 |
| A capable multimedia content discovery platform based on visual content analysis and intelligent data enrichment | 15.5 | 0 | 1 |
| Taxation of Private Equity and Hedge Fund Partnerships: Characterization of Carried Interest | 15.5 | 0 | 1 |
| Naxicap Partners | 15.5 | 0 | 1 |
| Broken Promises: Private Equity Bidding Behavior and the Value of Reputation | 15.5 | 0 | 1 |
| SEDE-GPS: socio-economic data enrichment based on GPS information | 15.5 | 0 | 1 |
| Brexit, Private Equity and Management | 15.5 | 0 | 1 |
| Access to private equity and real firm activity: Evidence from PIPEs | 15.5 | 0 | 1 |
| Corporate venture capital and the returns to acquiring portfolio companies☆ | 15.5 | 0 | 1 |
| MSG Afrika Investment Holdings | 15.5 | 0 | 1 |
| Bennett Rosenthal | 15.5 | 0 | 1 |
| David Kaplan | 15.5 | 0 | 1 |
| Use of Best Practice Strategies to Improve Longitudinal Study Participation: Analysis of Telephone Contact Data From the Northwest Regional Burn Model System | 15.5 | 0 | 1 |
| Lead enrichment at the surface of lead zirconate titanate thin films | 15.5 | 0 | 1 |
| Gatica: Linked Sensed Data Enrichment and Analytics Middleware for IoT Gateways | 15.5 | 0 | 1 |
| A habitat overlap analysis derived from maxent for tamarisk and the south-western willow flycatcher | 15.5 | 0 | 1 |
| Everstone | 15.5 | 0 | 1 |
| Unico Properties | 15.5 | 0 | 1 |
| Venture equity | 15.5 | 0 | 1 |
| Ontology-based functional classification of genes: Evaluation with reference sets and overlap analysis | 15.5 | 0 | 1 |
| A comparison of marketing teaching methods in North American and European universities | 15.5 | 0 | 1 |
| Weijian Shan | 15.5 | 0 | 1 |
| Health administrative data enrichment using cohort information: Comparative evaluation of methods by simulation and application to real data | 15.5 | 0 | 1 |
| Graciela Llaneza | 15.5 | 0 | 1 |
| Edward Tregaskiss Elbourne | 15.5 | 0 | 1 |
| The Contact-CTI Study: Use of Tissue Contact Data to Guide Atrial Flutter Ablation | 15.5 | 0 | 1 |
| Marshall Capital Partners | 15.5 | 0 | 1 |
| Bayesian inference of transmission chains using timing of symptoms, pathogen genomes and contact data | 15.5 | 0 | 1 |
| JOA: Joint Overlap Analysis of multiple genomic interval sets | 15.5 | 0 | 1 |
| Register of Private Equity Cases (NAID 41023755) | 15.5 | 0 | 1 |
| The Contact PVI Study: Use of Tissue Contact Data to Guide Atrial Fibrillation Ablation | 15.5 | 0 | 1 |
| Prelude Fertility | 15.5 | 0 | 1 |
| Northgate Capital | 15.5 | 0 | 1 |
| SKY Fund | 15.5 | 0 | 1 |
| Category:Sovereign wealth fund portfolio companies | 15.5 | 0 | 1 |
| Q65774340 | 15.5 | 0 | 1 |
| Thomas O. Hicks, Jr. | 15.5 | 0 | 1 |
| Secret and Confidential Account Data, Disclosure Records, and Messages (NAID 7694844) | 15.5 | 0 | 1 |
| commercialproperties24 | 15.5 | 0 | 1 |
| Crowd-Based Data Sourcing | 15.5 | 0 | 1 |
| THE REALIZATION ON PC-1500 COMPUTER TO PROCESS COMMON LEAD DATA | 15.5 | 0 | 1 |
| 2017-42 Private Equity Adviser Barred From Industry (NAID 144011809) | 15.5 | 0 | 1 |
| 2016-100 - SEC Private Equity Fund Adviser Acted As Unregistered Broker (NAID 144011359) | 15.5 | 0 | 1 |
| 2016-115 - Consultant to Chinese Private Equity Firms Settles Insider Trading Charges (NAID 144011387) | 15.5 | 0 | 1 |
| 2015-250 - SEC Charges Private Equity Firm and Four Executives With Failing to Disclose Conflicts of Interest (NAID 144011077) | 15.5 | 0 | 1 |
| 2015-204 SEC Charges Two Philadelphia Area Men For Defrauding Friends And Family In Private Equity Fund (NAID 144010985) | 15.5 | 0 | 1 |
| 2014-120 - SEC Charges Private Equity Firm With Pay-to-Play Violations, Political Campaign Contributions in Pennsylvania (NAID 144010225) | 15.5 | 0 | 1 |
| 2014-41 - SEC Announces Charges Against Arizona-Based Private Equity Fund Manager in Expense Misallocation Scheme (NAID 144010067) | 15.5 | 0 | 1 |
| 2014-19 - SEC Charges Manhattan-Based Private Equity Manager With Stealing $9 Million in Investor Funds (NAID 144010023) | 15.5 | 0 | 1 |
| 2013-160 - SEC Charges Former Oppenheimer Private Equity Fund Manager with Misleading Investors Valuation, Performance (NAID 144009753) | 15.5 | 0 | 1 |
| 2013-36 - SEC Charges Private Equity Firm, Former Executive, and Consultant for Improperly Soliciting Investments (NAID 144009507) | 15.5 | 0 | 1 |
| 2013-38 - SEC Charges New York-Based Private Equity Fund Advisers with Misleading Investors about Valuation and Performance (NAID 144009511) | 15.5 | 0 | 1 |
| 2012-244 - SEC Charges Chicago-Based Investment Adviser with Defrauding Investors in Failing Private Equity Fund (NAID 144009361) | 15.5 | 0 | 1 |
| 2012-191 - SEC Charges Chicago-Based Investment Firm with Misleading Investors in Private Equity Offerings (NAID 144009255) | 15.5 | 0 | 1 |
| 2010-58 - SEC Charges Private Equity Firm in Kickback Scheme Involving New York Pension Fund (NAID 144007915) | 15.5 | 0 | 1 |
| 2010-64 - SEC Charges Private Equity Firm and Money Manager for Defrauding Detroit-Area Public Pension Funds (NAID 144007927) | 15.5 | 0 | 1 |
| 2006-181 - SEC Adopts New Rules for Business Development Companies and Reproposes New Category of Eligible Portfolio Company (NAID 144006005) | 15.5 | 0 | 1 |
| Take it Personally - A Python library for data enrichment for infometrical applications | 15.5 | 0 | 1 |
| Web of Science versus Scopus: Journal Coverage Overlap Analysis | 15.5 | 0 | 1 |
| AVANT Private Equity investiční fond s proměnným základním kapitálem | 15.5 | 0 | 1 |
| KB Private Equity 3, uzavřený podílový fond Amundi Czech Republic, investiční společnost | 15.5 | 0 | 1 |
| KB Private Equity, uzavřený podílový fond, Amundi Czech Republic, investiční společnost | 15.5 | 0 | 1 |
| ČS PRIVATE EQUITY I - uzavřený podílový fond | 15.5 | 0 | 1 |
| BHS Fund II. - podfond BHS Private Equity Fund | 15.5 | 0 | 1 |
| KB Private Equity 2, uzavřený podílový fond, Amundi Czech Republic, investiční společnost | 15.5 | 0 | 1 |
| Becker Ventures | 15.5 | 0 | 1 |
| Foresight Group | 15.5 | 0 | 1 |
| Quantitative drug design studies. V. Approach to lead generation by pharmacophoric pattern searching | 15.5 | 0 | 1 |
| Q71688812 | 15.5 | 0 | 1 |
| A vendor consolidation scorecard for 2000 | 15.5 | 0 | 1 |
| Monitoring utilization of hypolipemic agents using an insurance company database | 15.5 | 0 | 1 |
| Drug-company data vaults to be opened | 15.5 | 0 | 1 |
| Hospitals tap external warehouses for marketing data | 15.5 | 0 | 1 |
| Local lead data are needed for local decision making | 15.5 | 0 | 1 |
| IOL (intraocular lense) prices continue sliding in the face of competition, vendor consolidation | 15.5 | 0 | 1 |
| Great Hill Partners | 15.5 | 0 | 1 |
| Under new management. Two private equity firms acquire design, building giant Marshall Erdman | 15.5 | 0 | 1 |
| Lisa T. Heffernan | 15.5 | 0 | 1 |
| Internet world despairs as non-profit .org sold for $$$$ to private equity firm, price caps axed | 15.5 | 0 | 1 |
| Business contacts | 15.5 | 0 | 1 |
| Physician practice management: a private equity investor's perspective | 15.5 | 0 | 1 |
| Business contacts | 15.5 | 0 | 1 |
| Tapping private equity to finance your dream | 15.5 | 0 | 1 |
| Overlap analysis of the West of Scotland coronary prevention study (WOSCOPS) | 15.5 | 0 | 1 |
| Lead generation--enhancing the success of drug discovery by investing in the hit to lead process | 15.5 | 0 | 1 |
| Vendor consolidation: still riding the wave. Plenty of buyers and sellers in 2006 as vendors tried to get footholds in growing niches | 15.5 | 0 | 1 |
| Fairness opinions in health care transactions--cause and effect: the emergence of private equity funds as a driving force in big and small transactions and the resulting increased use of fairness opinions | 15.5 | 0 | 1 |
| Tissue-targeting lead generation and optimization from random and directed screening of technetium-99m labeled tripeptide complex libraries in vivo | 15.5 | 0 | 1 |
| Automotive suppliers : SBC Scandinavian business contacts | 15.5 | 0 | 1 |
| Globe : international newsletter for the employees and business contacts of Hägglunds Denison | 15.5 | 0 | 1 |
| Outlook : a newsletter for the employees and business contacts of Boliden International Mining | 15.5 | 0 | 1 |
| Sales intelligence Europe : European edition | 15.5 | 0 | 1 |
| Swedish automotive suppliers : SCB Swedish business contacts | 15.5 | 0 | 1 |
| Swedish consultants : SBC Scandinavian business contacts | 15.5 | 0 | 1 |
| Lead enrichment in different genotypes of rice grains | 15.5 | 0 | 1 |
| Private equity groups take an interest in home health | 15.5 | 0 | 1 |
| Hit-to-Lead. Enhancing lead generation to accelerate quality compounds into lead optimization. 18-19 July 2005, London, UK | 15.5 | 0 | 1 |
| 'Marketing intelligence unit' to guide trusts into new era | 15.5 | 0 | 1 |
| Private equity still lurking. Apria deal shows sector still watching healthcare | 15.5 | 0 | 1 |
| Private equity investment in health care services | 15.5 | 0 | 1 |
| Private equity investment and nursing home care: is it a big deal? | 15.5 | 0 | 1 |
| Vendor consolidation: the wait is over | 15.5 | 0 | 1 |
| Lead generation and examples opinion regarding how to follow up hits | 15.5 | 0 | 1 |
| Private equity investment in home health care: is the window of opportunity beginning to close? | 15.5 | 0 | 1 |
| GENOVA: Gene Overlap Analysis of GWAS Results | 15.5 | 0 | 1 |
| Can a private equity firm own a dental practice? | 15.5 | 0 | 1 |
| Strategic investors: private equity fund expands and diversifies | 15.5 | 0 | 1 |
| data augmentation | 15.5 | 0 | 1 |
| Private equity firm invests in Willows Referral Service | 15.5 | 0 | 1 |
| Antin Infrastructure Partners | 15.5 | 0 | 1 |
| MerchantBridge | 15.5 | 0 | 1 |
| Lead generation: reality check on commonly held views | 15.5 | 0 | 1 |
| Vinci Partners | 15.5 | 0 | 1 |
| Niche overlap analysis of a lizard assemblage from the Atlantic Rainforest, evaluation of arsenic toxicity in cladocerans, and molecular biology of mycoplasmas | 15.5 | 0 | 1 |
| Correction: Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example | 15.5 | 0 | 1 |
| SOCRATES: An online tool leveraging a social contact data sharing initiative to assess mitigation strategies for COVID-19 | 15.5 | 0 | 1 |
| The Second Health Care Market: Market Mapping Based upon Consumer Perception | 15.5 | 0 | 1 |
| Private Equity in Ophthalmology and Optometry: Analysis of Acquisitions from 2012 through 2019 in the United States | 15.5 | 0 | 1 |
| Private Equity Acquisitions of Physician Medical Groups Across Specialties, 2013-2016 | 15.5 | 0 | 1 |
| Stalled Federal Efforts to End Surprise Billing - The Role of Private Equity | 15.5 | 0 | 1 |
| Hahnemann's Closure as a Lesson in Private Equity Healthcare | 15.5 | 0 | 1 |
| The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data | 15.5 | 0 | 1 |
| Combining serological and contact data to derive target immunity levels for achieving and maintaining measles elimination | 15.5 | 0 | 1 |
| Comment on: "Conflicts of interest for physician owners of private equity-owned medical practices" | 15.5 | 0 | 1 |
| Conflicts of interest for physician owners of private equity-owned medical practices | 15.5 | 0 | 1 |
| Bayesian inference of chromatin structure ensembles from population-averaged contact data | 15.5 | 0 | 1 |
| Defining Benchmark Outcomes for ALPPS | 15.5 | 0 | 1 |
| Content overlap analysis of 64 (hypo)mania symptoms among seven common rating scales | 15.5 | 0 | 1 |
| Market mapping and landscape analysis of human rabies biologicals in India | 15.5 | 0 | 1 |
| Lead generation and optimization of novel GPR119 agonists with a spirocyclic cyclohexane structure | 15.5 | 0 | 1 |
| Changing reimbursement models and private equity ownership in spine surgery | 15.5 | 0 | 1 |
| Advances in Lead Generation | 15.5 | 0 | 1 |
| Private Equity Acquisition of Physician Practices | 15.5 | 0 | 1 |
| Morgenthaler Partners | 15.5 | 0 | 1 |
| Evaluating systematic transactional data enrichment and reuse | 15.5 | 0 | 1 |
| Investigating the Behavior of Published PAINS Alerts Using a Pharmaceutical Company Data Set | 15.5 | 0 | 1 |
| Natural products: a strategic lead generation approach in crop protection discovery | 15.5 | 0 | 1 |
| Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data | 15.5 | 0 | 1 |
| Escaping from Flatland: [2 + 2] Photocycloaddition; Conformationally Constrained sp3-rich Scaffolds for Lead Generation | 15.5 | 0 | 1 |
| How to Computationally Stack the Deck for Hit-to-Lead Generation: In Silico Molecular Interaction Energy Profiling for de Novo siRNA Guide Strand Surrogate Selection | 15.5 | 0 | 1 |
| Private Equity Acquisition of Physician Practices | 15.5 | 0 | 1 |
| Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors | 15.5 | 0 | 1 |
| YPS Report: The Role of Private Equity in Medicine | 15.5 | 0 | 1 |
| The Emergence of Private Equity in Ophthalmology | 15.5 | 0 | 1 |
| Quantitative analysis of a rare disease network's international contact database and E-repository provides insights into biobanking in the electronic consent era | 15.5 | 0 | 1 |
| Implications of Private Equity Acquisition of Otolaryngology Physician Practices | 15.5 | 0 | 1 |
| The Database Dilemma: An Imperfect but Critical Tool to Improve Quality and Benchmark Outcomes | 15.5 | 0 | 1 |
| Physician Practice Management and Private Equity: Market Forces Drive Change | 15.5 | 0 | 1 |
| Potential Implications of Private Equity Investments in Health Care Delivery | 15.5 | 0 | 1 |
| Private Equity Investment in Behavioral Health Treatment Centers | 15.5 | 0 | 1 |
| Focusing on Relevance: CETSA-Guided Medicinal Chemistry and Lead Generation | 15.5 | 0 | 1 |
| Tuberculosis from transmission in clinics in high HIV settings may be far higher than contact data suggest | 15.5 | 0 | 1 |
| Private Equity and Dermatology-First, Do No Harm | 15.5 | 0 | 1 |
| Trends in Private Equity Acquisition of Dermatology Practices in the United States | 15.5 | 0 | 1 |
| David S. Lobel Professorship in Private Equity | 15.5 | 0 | 1 |
| Private Equity Investment in Health Care | 15.5 | 0 | 1 |
| Private Equity Investment in Health Care-Reply | 15.5 | 0 | 1 |
| Response to letter to the editor from Bennett and further thoughts on the corporatization of dermatology and private equity-backed dermatology groups | 15.5 | 0 | 1 |
| Potential Genes Related to Levofloxacin Resistance in Mycobacterium tuberculosis Based on Transcriptome and Methylome Overlap Analysis | 15.5 | 0 | 1 |
| A Day at the Office: Private Practice and Private Equity | 15.5 | 0 | 1 |
| Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review | 15.5 | 0 | 1 |
| Lead Identification of 8-(Methylamino)-2-oxo-1,2-dihydroquinoline Derivatives as DNA Gyrase Inhibitors: Hit-to-Lead Generation Involving Thermodynamic Evaluation | 15.5 | 0 | 1 |
| Private equity and anesthesiology groups: Implications to cost and quality of anesthesia care | 15.5 | 0 | 1 |
| Implications of Private Equity in Oral and Maxillofacial Surgery | 15.5 | 0 | 1 |
| Doctor Patient Unity | 15.5 | 0 | 1 |
| Private Equity Acquisition of Physician Practices | 15.5 | 0 | 1 |
| Trend: provider-vendor consolidation. The urge to merge | 15.5 | 0 | 1 |
| Quality of care for people with dementia. Registries charting epidemiological trends and benchmark outcomes are required | 15.5 | 0 | 1 |
| Private Equity-Backed Hospital Investments and the Impact of the Coronavirus Disease 2019 (COVID-19) Epidemic | 15.5 | 0 | 1 |
| The Growth Of Private Equity Investment In Health Care: Perspectives From Ophthalmology | 15.5 | 0 | 1 |
| PROXENTA Private Equity | 15.5 | 0 | 1 |
| BGH Capital | 15.5 | 0 | 1 |
| SOCRATES: an online tool leveraging a social contact data sharing initiative to assess mitigation strategies for COVID-19 | 15.5 | 0 | 1 |
| Dissimilarity-Overlap analysis of replicate enrichment communities | 15.5 | 0 | 1 |
| GK Investment | 15.5 | 0 | 1 |
| The evolution of private equity in dermatology | 15.5 | 0 | 1 |
| Dermatology resident perspectives on practice ownership structures and private equity-backed group practices | 15.5 | 0 | 1 |
| NIM Marketing Intelligence Review | 15.5 | 0 | 1 |
| Institutional Review Board Quality, Private Equity, and Promoting Ethical Human Subjects Research | 15.5 | 0 | 1 |
| Re: Private Equity Acquisitions of Physician Medical Groups Across Specialties, 2013-2016 | 15.5 | 0 | 1 |
| Lead Generation for Human Mitotic Kinesin Eg5 using Structure-based Virtual Screening and Validation by in vitro and Cell-based Assays | 15.5 | 0 | 1 |
| Activity-directed synthesis: A flexible approach for lead generation | 15.5 | 0 | 1 |
| RSBC Holding | 15.5 | 0 | 1 |
| Private Equity's Game Plan and Why it Should Matter to Us | 15.5 | 0 | 1 |
| Private Equity, Women's Health, and the Corporate Transformation of American Medicine | 15.5 | 0 | 1 |
| Expansion of Private Equity Involvement in Women's Health Care | 15.5 | 0 | 1 |
| Changes in Hospital Income, Use, and Quality Associated With Private Equity Acquisition | 15.5 | 0 | 1 |
| Defining Benchmark Outcomes for Pancreatoduodenectomy With Portomesenteric Venous Resection | 15.5 | 0 | 1 |
| US Congress investigates effects of $80bn private equity industry on government healthcare programme | 15.5 | 0 | 1 |
| Pale Fire Capital | 15.5 | 0 | 1 |
| Integrated Technology of Heterogeneous Business Data for Enterprise Networking Manufacture Based on Groupware BAPI | 15.5 | 0 | 1 |
| "Private Equity and the Private Practice of Medicine" | 15.5 | 0 | 1 |
| Growth of Private Equity in Dermatology Through Acquisitions and New Clinic Formation, 2018-2019 | 15.5 | 0 | 1 |
| Re: The Growth of Private Equity Investment in Health Care: Perspectives from Ophthalmology | 15.5 | 0 | 1 |
| Using Flint, Michigan, lead data in introductory statistics | 15.5 | 0 | 1 |
| Characteristics of Private Equity-Owned Hospitals in 2018 | 15.5 | 0 | 1 |
| Elwin Huaman | 15.5 | 0 | 1 |
| SYNERGY PRIVATE EQUITY FUND project | 15.5 | 0 | 1 |
| Capital Alliance Private Equity III Limited ("Cape III", or "the Fund") project | 15.5 | 0 | 1 |
| Byblos Private Equity Fund project | 15.5 | 0 | 1 |
| SYNERGY PRIVATE EQUITY FUND II project | 15.5 | 0 | 1 |
| MAGHREB PRIVATE EQUITY FUND IV project | 15.5 | 0 | 1 |
| Ethical concerns regarding private equity in Right to Try in the USA | 15.5 | 0 | 1 |
| Business Data Categorization and Refinement for Application in Longitudinal Neighborhood Health Research: a Methodology | 15.5 | 0 | 1 |
| CHESS enables quantitative comparison of chromatin contact data and automatic feature extraction | 15.5 | 0 | 1 |
| Barry Bekkedam | 15.5 | 0 | 1 |
| ORCID for Wikidata. Data enrichment for scientometric applications | 15.5 | 0 | 1 |
| Comparative Performance of Private Equity-Owned US Nursing Homes During the COVID-19 Pandemic | 15.5 | 0 | 1 |
| University of Oxford Private Equity Institute | 15.5 | 0 | 1 |
| New Zealand Business Number (Primary Business Data) Order 2018 | 15.5 | 0 | 1 |
| Private Equity Investments in Women's Health and Obstetrics and Gynecology Practices | 15.5 | 0 | 1 |
| Trends in Private Equity Deals in Oral and Maxillofacial Surgery and Dentistry | 15.5 | 0 | 1 |
| Real-world efficacy of deep TMS for obsessive-compulsive disorder: Post-marketing data collected from twenty-two clinical sites | 15.5 | 0 | 1 |
| AVANT Private Equity 2 SICAV | 15.5 | 0 | 1 |
| MBK Partners | 15.5 | 0 | 1 |
| J&T Private Equity | 15.5 | 0 | 1 |
| Tenzing | 15.5 | 0 | 1 |
| Should surgeons consider partnering with private equity investors? | 15.5 | 0 | 1 |
| Private Equity Transactions: Perceptions of U.S. Vitreoretinal Surgery Fellows | 15.5 | 0 | 1 |
| Private Equity Circles German Firm With Nazi Past | 15.5 | 0 | 1 |
| Growth Catalyst Partners | 15.5 | 0 | 1 |
| Ripplewood Holdings | 15.5 | 0 | 1 |
| EQT Private Capital Asia | 15.5 | 0 | 1 |
| Can Investors Time Their Exposure to Private Equity? | 15.5 | 0 | 1 |
| The Economic Effects of Private Equity Buyouts | 15.5 | 0 | 1 |
| Private Equity, Jobs, and Productivity | 15.5 | 0 | 1 |
| Private Equity and Employment | 15.5 | 0 | 1 |
| Does Private Equity Investment in Healthcare Benefit Patients? Evidence from Nursing Homes | 15.5 | 0 | 1 |
| Has Persistence Persisted in Private Equity? Evidence from Buyout and Venture Capital Funds | 15.5 | 0 | 1 |
| Private Equity Indices Based on Secondary Market Transactions | 15.5 | 0 | 1 |
| Financial Intermediation in Private Equity: How Well Do Funds of Funds Perform? | 15.5 | 0 | 1 |